Single-Walled Carbon Nanotubes Deliver Peptide Antigen into Dendritic Cells and Enhance IgG Responses to Tumor-Associated Antigens

We studied the feasibility of using single-wall carbon nanotubes (SWNTs) as antigen carriers to improve immune responses to peptides that are weak immunogens, a characteristic typical of human tumor antigens. Binding and presentation of peptide antigens by the MHC molecules of antigen presenting cells (APCs) is essential to mounting an effective immune response. The Wilm’s tumor protein (WT1) is upregulated in many human leukemias and cancers and several vaccines directed at this protein are in human clinical trials. WT1 peptide 427 induces human CD4 T cell responses in the context of multiple human HLA-DR.B1 molecules, but the peptide has a poor binding affinity to BALB/c mouse MHC class II molecules. We used novel, spectrally quantifiable chemical approaches to covalently append large numbers of peptide ligands (0.4 mmol/g) onto solubilized SWNT scaffolds. Peptide-SWNT constructs were rapidly internalized into professional APCs (dendritic cells and macrophages) within minutes in vitro, in a dose dependent manner. Immunization of BALB/c mice with the SWNT–peptide constructs mixed with immunological adjuvant induced specific IgG responses against the peptide, while the peptide alone or peptide mixed with the adjuvant did not induce such a response. The conjugation of the peptide to SWNT did not enhance the peptide-specific CD4 T cell response in human and mouse cells, in vitro. The solubilized SWNTs alone were nontoxic in vitro, and we did not detect antibody responses to SWNT in vivo. These results demonstrated that SWNTs are able to serve as antigen carriers for delivery into APCs to induce humoral immune responses against weak tumor antigens.

[1]  Donald R McCrimmon,et al.  Biocompatible nanoscale dispersion of single-walled carbon nanotubes minimizes in vivo pulmonary toxicity. , 2010, Nano letters.

[2]  A. Farkas,et al.  Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. , 2010, Seminars in immunology.

[3]  David Leong,et al.  Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. , 2007, Molecular pharmaceutics.

[4]  R. Steinman,et al.  Developmental regulation of MHC class II transport in mouse dendritic cells , 1997, Nature.

[5]  C. Melief Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[6]  M. Plebanski,et al.  Promising particle-based vaccines in cancer therapy , 2008, Expert review of vaccines.

[7]  M. Prato,et al.  Intracellular Trafficking of Carbon Nanotubes by Confocal Laser Scanning Microscopy , 2007 .

[8]  D. Scheinberg,et al.  Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells , 2007, Clinical Cancer Research.

[9]  Magnus Bergkvist,et al.  Paradoxical glomerular filtration of carbon nanotubes , 2010, Proceedings of the National Academy of Sciences.

[10]  M. Prato,et al.  Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. , 2007, Nature nanotechnology.

[11]  C Danieli,et al.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.

[12]  M. Prato,et al.  Amino acid functionalisation of water soluble carbon nanotubes. , 2002, Chemical communications.

[13]  S. Moghimi,et al.  Complement monitoring of carbon nanotubes. , 2010, Nature nanotechnology.

[14]  J. Wolchok,et al.  Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. , 2010, Blood.

[15]  W. Travis,et al.  WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer , 2010, Cancer Immunology, Immunotherapy.

[16]  A. Houghton,et al.  Immune recognition of self in immunity against cancer. , 2004, The Journal of clinical investigation.

[17]  Heath Aw Cytokines as immunological adjuvants. , 1995 .

[18]  M. Prato,et al.  Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. , 2006, Nano letters.

[19]  C. Kojima Design of stimuli-responsive dendrimers , 2010, Expert opinion on drug delivery.

[20]  O. Finn,et al.  Tumor antigens and tumor antigen discovery. , 2005, Cancer treatment and research.

[21]  Maurizio Prato,et al.  Immunization with peptide-functionalized carbon nanotubes enhances virus-specific neutralizing antibody responses. , 2003, Chemistry & biology.

[22]  Jonathan J. Lewis,et al.  Heteroclitic Immunization Induces Tumor Immunity , 1998, The Journal of experimental medicine.

[23]  M. L. Mackichan,et al.  Recent developments in adjuvants for vaccines against infectious diseases. , 2001, Biomolecular engineering.

[24]  Jie Li,et al.  Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1 , 2004, The Journal of Immunology.

[25]  R. Steinman,et al.  The endocytic activity of dendritic cells , 1995, The Journal of experimental medicine.

[26]  P. Srivastava,et al.  Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. , 1998, Immunity.

[27]  K Kostarelos,et al.  Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. , 2009, Nature nanotechnology.

[28]  C. Watts,et al.  Antigen Traffic Pathways in Dendritic Cells , 2000, Traffic.

[29]  D. Scheinberg,et al.  A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease , 2008, Leukemia.

[30]  P. Livingston,et al.  Cancer Vaccines Targeting Carbohydrate Antigens , 2006, Human vaccines.

[31]  S. Trohalaki Cellular Uptake of Functionalized Carbon Nanotubes Shown to be Energy-Dependent , 2006 .

[32]  H. Dai,et al.  Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Bayır,et al.  Phosphatidylserine Targets Single-Walled Carbon Nanotubes to Professional Phagocytes In Vitro and In Vivo , 2009, PloS one.

[34]  P. Livingston,et al.  Antibody inducing polyvalent cancer vaccines. , 2005, Cancer treatment and research.

[35]  A. Prescott,et al.  The coated pit and macropinocytic pathways serve distinct endosome populations , 1994, The Journal of cell biology.

[36]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[37]  B. Reina-San-Martin,et al.  Lymphocyte polyclonal activation: a pitfall for vaccine design against infectious agents. , 2000, Parasitology today.

[38]  E. Kaiser,et al.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.

[39]  A. Heath,et al.  Cytokines as immunological adjuvants. , 1995, Pharmaceutical biotechnology.